A Phase II, Multi-Center, Randomized, Double-Blind, Parallel-Group Placebo-Controlled Study to Evaluate Efficacy and Safety of RO4917838 in Combination with Selective Serotonin Reuptake Inhibitors in Patients with Obsessive Compulsive Disorder

ID Number 12-1148

Principal Investigator(s)

Department(s) or Division(s)


Despite advances in the treatment of Obsessive Compulsive Disorder (OCD), most patients continue to experience disabling symptoms leading to impaired functioning and diminished quality of life. There remains a need to develop more effective and better tolerated long-term treatments for OCD.

This 21 -week, multicenter, randomized, double-blind, parallel-group, placebo-controlled study examines whether patients treated with bitopertin and a selective serotonin reuptake inhibitor (SSRI) experience fewer symptoms compared with those treated with SSRI only, a currently recommended treatment for OCD.

Contact Information
Resham Gellatly
(212) 659-1677

Recruiting Patients: Yes